micro-RNAs dependent regulation of DNMT and HIF1α gene expression in thrombotic disorders

Vijay, Aatira; Jha, Pawan Kumar; Garg, Iti; Sharma, Manish; Ashraf, Mohammad Zahid; Kumar, Bhuvnesh

doi:10.1038/s41598-018-38057-6

Cited by 10 publications

(8 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NETs are cytotoxic and procoagulant, in part due to the release of DNA-histone complexes and double-stranded DNA, histones, and HMGB1 [ 41 , 42 ]. It is understood that the increase in DNA-binding proteins, extracellular ribosomal RNA, and micro-RNAs, may be related to thrombosis [ 43 , 44 ].…”

Section: Introductionmentioning

confidence: 99%

Mechanisms of Immunothrombosis by SARS-CoV-2

et al. 2021

View full text Add to dashboard Cite

SARS-CoV-2 contains certain molecules that are related to the presence of immunothrombosis. Here, we review the pathogen and damage-associated molecular patterns. We also study the imbalance of different molecules participating in immunothrombosis, such as tissue factor, factors of the contact system, histones, and the role of cells, such as endothelial cells, platelets, and neutrophil extracellular traps. Regarding the pathogenetic mechanism, we discuss clinical trials, case-control studies, comparative and translational studies, and observational studies of regulatory or inhibitory molecules, more specifically, extracellular DNA and RNA, histones, sensors for RNA and DNA, as well as heparin and heparinoids. Overall, it appears that a network of cells and molecules identified in this axis is simultaneously but differentially affecting patients at different stages of COVID-19, and this is characterized by endothelial damage, microthrombosis, and inflammation.

show abstract

Section: Introductionmentioning

confidence: 99%

Mechanisms of Immunothrombosis by SARS-CoV-2

et al. 2021

View full text Add to dashboard Cite

show abstract

“…c-Myc is upregulated in prostate cancer cells and inhibits miR-23a and miR-23b at the transcriptional level, resulting in its target protein mitochondrial glutaminase overexpression [ 35 ]. Using miRNA microarray meta-analysis, it was found that miR-23b was associated with hypoxia-related pathways mediated by the HIF gene family, which revealed the important role of miR-23b in hypoxia and thrombosis pathway [ 36 ]. E2F1 binding sequence participates in the expression of C9orf3 transcripts of host genes in miR-23b/27b/24 clusters, thus promoting cell migration [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

Microarray profile analysis identifies ETS1 as potential biomarker regulated by miR-23b and modulates TCF4 in gastric cancer

Mei¹,

Qi²,

Xia³

et al. 2021

World J Surg Onc

View full text Add to dashboard Cite

Background Gastric cancer (GC), a common malignancy of the human digestive system, represents the second leading cause of cancer-related deaths worldwide. Early detection of GC has a significant impact on clinical outcomes. The aim of this study was to identify potential GC biomarkers. Methods In this study, we conducted a multi-step analysis of expression profiles in GC clinical samples downloaded from TCGA database to identify differentially expressed miRNAs (DEMs) and differentially expressed mRNAs (DEGs). Potential prognostic biomarkers from the available DEMs were then established using the Cox regression method. Gene ontology and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed to investigate the biological role of the predicted target genes of the miRNA biomarkers. Then, the prognostic DEM-mediated regulatory network was constructed based on transcription factor (TF)–miRNA–target interaction. Subsequently, the consensus genes were further determined based on the overlap between DEGs and these target genes of DEMs. Besides, expression profile, co-expression analysis, immunity, and prognostic values of these prognostic genes were also investigated to further explore the roles in the mechanism of GC tumorigenesis. Results We got five miRNAs, including miR-23b, miR-100, miR-143, miR-145, and miR-409, which are associated with the overall survival of GC patients. Subsequently, enrichment analysis of the target genes of the miRNA biomarkers shown that the GO biological process terms were mainly enriched in mRNA catabolic process, nuclear chromatin, and RNA binding. In addition, the KEGG pathways were significantly enriched in fatty acid metabolism, extracellular matrix (ECM) receptor interaction, and proteoglycans in cancer pathways. The transcriptional regulatory network consisting of 68 TFs, 4 DEMs, and 58 targets was constructed based on the interaction of TFs, miRNAs, and targets. The downstream gene ETS1 of miR-23b and TCF4 regulated by ETS1 were obtained by the regulatory network construction and co-expression analysis. High expression of ETS1 and TCF4 indicated poor prognosis in GC patients, particularly in the advanced stages. The expression of ETS1 and TCF4 was correlated with CD4+ T cells, CD8+ T cells, and B cells. Conclusions miR-23b, ETS1, and TCF4 were identified as the prognostic biomarkers. ETS1 and TCF4 had potential immune function in GC, which provided a theoretical basis for molecular-targeted combined immunotherapy in the future.

show abstract

“…We searched for studies published in EMBASE, Medline, PubMed, Web of Science, and the Cochrane Clinical Trials Database between January 2000 and October 2021, using the keywords: (1) rivaroxaban; (2) warfarin; (3) venous thromboembolism; and (4) bleeding. Combinations of keywords using the Boolean operators "and/or" were adopted for the search strategy.…”

Section: Study Selectionmentioning

confidence: 99%

Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis

et al. 2023

View full text Add to dashboard Cite

BackgroundAnticoagulant treatment is used to treat and prevent venous thromboembolism (VTE). However, the relative effectiveness of newer anticoagulants vs. warfarin has not been appraised.ObjectiveThe aim was to evaluate the safety and efficacy of rivaroxaban for VTE in comparison to warfarin.Materials and methodsFrom January 2000 until October 2021, all related studies were collected by EMBASE, the Cochrane Library, PubMed and Web of Scienceand. During the review process, two reviewers independently analyzed the included studies, including quality evaluation, screening and data extraction. We focused on VTE events as our primary outcomes.ResultsIn total, 20 trials were retrieved. These studies involved 230,320 patients, of which 74,018 received rivaroxaban and 156,302 received warfarin. Compared with warfarin, the incidence of VTE in rivaroxaban is significantly lower (risk ratio (RR) 0.71, 95% confidence interval (CI) [0.61, 0.84]; P < 0.0001, random effect model), and signiﬁcantly reduced major [RR: 0.84, 95% CI (0.77, 0.91); P < 0.0001, fixed effect model] and nonmajor [RR: 0.55, 95% CI (0.41, 0.74); P < 0.0001, fixed effect model] bleeding. No signiﬁcant differences in all-cause mortality between the two groups [RR: 0.68, 95% CI (0.45, 1.02); P = 0.06, fixed effect model].ConclusionRivaroxaban significantly reduced the incidence of VTE compared to warfarin in this meta-analysis. In order to verify these findings, larger sample sizes are required in well-designed studies.

show abstract

micro-RNAs dependent regulation of DNMT and HIF1α gene expression in thrombotic disorders

Cited by 10 publications

References 78 publications

Mechanisms of Immunothrombosis by SARS-CoV-2

Mechanisms of Immunothrombosis by SARS-CoV-2

Microarray profile analysis identifies ETS1 as potential biomarker regulated by miR-23b and modulates TCF4 in gastric cancer

Rivaroxaban vs. warfarin for the treatment and prevention of venous thromboembolism: A meta-analysis

Contact Info

Product

Resources

About